Supplementary Table 5. Clopidogrel-aspirin versus aspirin on clinical outcome stratified by ABCD-GENE score ≥10 or <10

Outcome	ABCD-GENE score* <10, n (%)						ABCD-GENE score* ≥10, n (%)						*P* for interaction
	Aspirin (n=1,915)	Clopidogrel-aspirin (n=1,849)	HR or RR‖ (95% CI)	*P*	Adjusted HR or RR‖¶ (95%CI)	Adjusted *P*¶	Aspirin (n=458)	Clopidogrel-aspirin (n=471)	HR or RR‖ (95% CI)	*P*	Adjusted HR or RR‖¶ (95% CI)	Adjusted *P*¶	
Primary efficacy outcome													
Stroke, including ischemic and hemorrhagic stroke	164 (8.6)	124 (6.7)	0.77 (0.61–0.98)	0.03	0.78 (0.62–0.99)	0.04	35 (7.6)	34 (7.2)	0.93 (0.58–1.50)	0.77	0.93 (0.58–1.50)	0.78	0.48
Secondary efficacy outcome													
Composite events†	166 (8.7)	126 (6.8)	0.78 (0.62–0.98)	0.03	0.78 (0.62–0.99)	0.04	36 (7.9)	35 (7.4)	0.93 (0.59–1.49)	0.77	0.94 (0.59–1.49)	0.78	0.48
Ischemic stroke	160 (8.4)	117 (6.3)	0.75 (0.59–0.95)	0.02	0.75 (0.59–0.96)	0.02	35 (7.6)	32 (6.8)	0.88 (0.54–1.42)	0.59	0.89 (0.55–1.43)	0.62	0.56
Recurrent stroke	118 (6.2)	95 (5.1)	0.82 (0.63–1.08)	0.16	0.83 (0.63–1.08)	0.17	25 (5.5)	24 (5.1)	0.92 (0.53–1.61)	0.77	0.93 (0.53–1.64)	0.81	0.72
Poor functional outcome‡	195 (10.2)	155 (8.4)	0.82 (0.70–0.96)	0.01	0.82 (0.71–0.96)	0.01	67 (14.6)	43 (9.1)	0.62 (0.43–0.92)	0.02	0.63 (0.43–0.92)	0.02	0.18
Primary safety outcome													
Moderate to severe bleeding§	8 (0.4)	15 (0.8)	1.95 (0.83–4.59)	0.13	2.03 (0.86–4.79)	0.11	2 (0.4)	2 (0.4)	0.97 (0.14–6.87)	0.97	1.06 (0.14–8.18)	0.95	0.52
Secondary safety outcome													
Death from any cause	13 (0.7)	17 (0.9)	1.36 (0.66–2.80)	0.41	1.38 (0.67–2.85)	0.38	7 (1.5)	8 (1.7)	1.11 (0.40–3.05)	0.84	1.16 (0.42–3.21)	0.78	0.75
Any bleeding§	40 (2.1)	50 (2.7)	1.30 (0.86–1.97)	0.22	1.32 (0.87–2.00)	0.19	7 (1.5)	10 (2.1)	1.39 (0.53–3.65)	0.51	1.45 (0.55–3.84)	0.45	0.90

Values are presented as n (%) unless otherwise indicated.

HR, hazard ratio; RR, relative risk; CI, confidence interval; BMI, body mass index.

*ABCD-GENE score was calculated by factors of age, BMI, chronic kidney diseases, diabetes, and *CYP2C19* genotyping, which ranged from 0 to 34 (higher ABCD-GENE score indicating high platelet reactivity); †Composite event included stroke, myocardial infarction, or death from cardiovascular causes; ‡Poor functional outcome included modified Rankin Scale scores of 2 to 6. Modified Rankin Scale scores range from 0 to 6, with higher scores indicating more disability; §Bleeding events were defined in accordance with the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria; ‖RRs were shown for poor functional outcomes. HRs were shown for other outcomes; ¶Adjusted for age, gender, BMI, history of hypertension, diabetes, dyslipidemia, previous ischemic stroke, and current smoking.